Last updated on August 12th, 2020 at 01:18 am
Vice-chancellor of Banaras Hindu University (BHU), Prof. Rakesh Bhatnagar and Prof. Atul Kumar Johri of JNU along with the team of scientists has achieved a great achievement. Scientists here have developed a vaccine against the streptococcal, a dangerous throat infection.
While the whole world is battling against an unprecedented epidemic COVID-19, the scientific world is also working day and night to find vaccines against COVID-19. In such a situation, the Vice-Chancellor of Banaras Hindu University, Prof. Rakesh Bhatnagar and Prof. Atul Kumar Johri, Jawaharlal Nehru University including the team of scientists has achieved a major achievement. The team of researchers has developed a vaccine against Streptococcal Infections, a dangerous throat infection.
- Scientists of BHU and JNU achieved big achievement
- Streptococcal Vaccine Claim Dangerous Throat Infections
- Cross Protective Vaccine Detected by Reverse Vaccinology
- Antibiotic antibodies develop during immunization in mice
Here is the tweets from the officials:
With all your good wishes published in nature communications about a universal vaccine against streptococcal infections today here is the linkhttps://t.co/rN3lpHTvnq
— Prof Atul K Johri (@ProfJohri) July 15, 2020
In a breakthrough study, VC, Prof. Rakesh Bhatnagar,has co-authored a research paper on #vaccine against Streptococcal infections.The paper“Cross-serotype protection against group A Streptococcal infections induced by immunization with SPy_2191”has been published in @NatureComms. pic.twitter.com/pXYA6v4j8Q
— BHU Official (@bhupro) July 15, 2020
This infection is affecting the health of millions of people worldwide and killing more than five lakh people every year. There is currently no vaccine to treat this infection. This historical study is published on 15 July in the internationally prestigious paper, Nature Communication.
First test done on mice
According to BHU’s Vice-Chancellor Professor Rakesh Bhatnagar, this vaccine was tested against several serotypes in mice. Which led to 70 to 90 per cent immunization results. Professor Rakesh Bhatnagar started the study about three years ago with JNU professor Atul Kumar Johri and other researchers.
Applied for Patent
Patents have been applied for in this regard, and the team is now waiting for a company to come forward to work towards pre-clinical studies and human testing of vaccines and to reach the vaccine market. He said that the team of scientists detected the cross-protective vaccine using reverse vaccinology. In this process, anti-bacterial antibodies evolved during immunization in mice which destroyed Group A Streptococcus (GAS) bacteria present in serotypes of different geographical regions. The study showed immunity from 76 to 92% of the GAS serotype.
This bacteria gives rise to dangerous throat infections
Streptococcus pyogenes is a common bacteria responsible for dangerous throat infections. These bacteria, also known as Group A Streptococcus (GAS), are the cause of throat irritation, pus-causing diseases. This highly contagious skin infection that is mainly found in newborns and children, causes soft tissue infections, streptococcal toxic shock syndrome, group A Streptococcus (GAS), high fever and heart related diseases. Group A Streptococcus causes 61.6 million cases of pharyngitis (throat irritation) annually and 18 million cases of severe malaise.
Streptococcus pyogenes is the ninth most infectious bacteria in the category of smallpox, Haemophilia influenza type B and hepatitis B, when viewed critically ill and mortality. It mainly causes severe malaise and high mortality in low and middle-income countries. The unavailability of data, mainly in South Asia and Sub-Saharan African countries, does not give a true picture of GAS cases. Prof. Rakesh Bhatnagar has also played a leading role in finding anthrax vaccine and rabies DNA vaccine in the past. He noted that the results of his study on streptococcal infection are of utmost importance from a broad interest perspective.